Alliancebernstein L.P. Grows Position in Amedisys, Inc. (NASDAQ:AMED)

Alliancebernstein L.P. boosted its position in shares of Amedisys, Inc. (NASDAQ:AMED - Free Report) by 2.0% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 677,787 shares of the health services provider's stock after purchasing an additional 13,587 shares during the quarter. Alliancebernstein L.P. owned about 2.07% of Amedisys worth $61,536,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Blue Trust Inc. lifted its position in shares of Amedisys by 55.1% during the fourth quarter. Blue Trust Inc. now owns 349 shares of the health services provider's stock valued at $34,000 after buying an additional 124 shares during the last quarter. HBW Advisory Services LLC acquired a new stake in shares of Amedisys in the 4th quarter worth $38,000. Versant Capital Management Inc grew its stake in Amedisys by 68.5% during the 4th quarter. Versant Capital Management Inc now owns 450 shares of the health services provider's stock worth $41,000 after buying an additional 183 shares during the last quarter. Vestcor Inc acquired a new position in Amedisys during the 4th quarter valued at about $73,000. Finally, Venturi Wealth Management LLC raised its stake in Amedisys by 397.4% in the fourth quarter. Venturi Wealth Management LLC now owns 975 shares of the health services provider's stock valued at $89,000 after buying an additional 779 shares during the last quarter. 94.36% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, Stephens reaffirmed an "equal weight" rating and issued a $101.00 price objective on shares of Amedisys in a research report on Tuesday, March 4th. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat, Amedisys has a consensus rating of "Hold" and an average target price of $101.00.

Remove Ads

Amedisys Stock Performance

Shares of AMED stock traded down $0.53 during mid-day trading on Thursday, reaching $91.50. The stock had a trading volume of 31,682 shares, compared to its average volume of 398,469. Amedisys, Inc. has a 1-year low of $82.15 and a 1-year high of $98.95. The firm has a market cap of $3.00 billion, a price-to-earnings ratio of 36.31, a PEG ratio of 1.78 and a beta of 0.89. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.05. The business's fifty day moving average is $92.23 and its 200-day moving average is $92.13.

Amedisys (NASDAQ:AMED - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The health services provider reported $0.96 earnings per share for the quarter, missing the consensus estimate of $1.05 by ($0.09). The business had revenue of $598.05 million during the quarter, compared to analyst estimates of $602.38 million. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. On average, research analysts forecast that Amedisys, Inc. will post 4.4 earnings per share for the current year.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.